Investigators and Program Directors

Select Publications

• Miller, TW.and Messer, A. Intrabody applications in neurological disorders: progress and future prospects. Mol. Therapy 12, 394-401 (2005)
• Wolfgang W, Miller T, Webster JM, Huston J, Thompson L, Marsh JL, and Messer A. Suppression of Huntington's Disease pathology in Drosophila by intracellular antibodies. Proc Natl Acad Sci USA 102, 11563-11568 (2005)
• Colby, DW, Chu, Y, Cassady, J, Duennwald, M, Zazulak, H, Webster, JM, Messer, A., Lindquist, S, Ingram, VM; and Wittrup, KD. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single domain intrabody. Proc. Natl. Acad. Sci, 101, 17616-17621 (2004)
• Miller TW, Zhou C, Gines S, MacDonald ME, Mazarakis ND, Bates GP, Huston JS, and Messer, A. A human single-chain Fv intrabody preferentially targets amino-terminal huntingtin fragments in striatal models of Huntington's Disease, Neurobiology of Disease, 19, 47-56 (2005)
• Zhou, C., Emadi, S., Sierks, MR and Messer, A., A human anti-alpha-synuclein intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol. Therapy, 10, 1023-1031 (2004)
• Shirley TL and Messer A. Early postnatal Purkinje cells from staggerer mice undergo aberrant development in vitro with characteristic morphologic and gene expression abnormalities. Dev Brain Res, 152, 153-157 (2004)
• Emadi, S., Liu,R., Yuan,B. Schulz,P., McAllistar, C., Lyubchenko,Y., Messer, A. and Sierks, M.R. Inhibiting aggregation of alpha-synuclein with human single-chain antibody fragments. Biochemistry 43, 2871-2878 (2004)
• Bolivar, V. J., Manley, K. and Messer, A. Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice. Brain Res. 1005, 29-35. (2004)
• Murphy, RC and Messer, A. A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease. Mol. Brain Res. 121:141-145 (2004)
• Bolivar, V. J., Manley, K. & Messer. A. (2003). Exploratory activity and fear conditioning abnormalities develop early in R6/2 Huntington's disease transgenic mice. Behav. Neurosci. 117:1233-1242 (2003)
• Miller, TW, Shirley, TL Wolfgang, WJ, Kang, X, and Messer, A. DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype. Mol. Therapy 7, 572-579 (2003)
• Lecerf, J.M., Shirley, TL, Zhu, Q, Kazantsev, A, Amersdorfer, P, Housman, DE, Messer, A., and Huston, JS. Human single- chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's Disease, Proc Natl Acad Sci USA 98:4764-4769 (2001)

Contact Information

E-mail:messer@wadsworth.org.